These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9818641)

  • 1. Inhibitors of tumor necrosis factor in rheumatoid arthritis: Will that dog hunt?
    Kavanaugh A; Cohen S; Cush J
    J Rheumatol; 1998 Nov; 25(11):2049-53. PubMed ID: 9818641
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor necrosis factor inhibitor therapy for rheumatoid arthritis.
    Naguwa SM
    Ann N Y Acad Sci; 2005 Jun; 1051():709-15. PubMed ID: 16127011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W
    Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?
    Lu CY; Williams KM; March L; Bertouch JV; Day RO
    Med J Aust; 2004 Oct; 181(8):457; discussion 457-8. PubMed ID: 15487967
    [No Abstract]   [Full Text] [Related]  

  • 5. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHARMAC responds on TNF inhibitors for inflammatory arthritis.
    Metcalfe S; Moodie P; Grocott R; Wilkinson T
    N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039
    [No Abstract]   [Full Text] [Related]  

  • 7. Will our current success in treating rheumatoid arthritis hinder new drug development? That is the question!!
    Weinblatt ME
    Ann Rheum Dis; 2005 Nov; 64(11):1529-31. PubMed ID: 16126790
    [No Abstract]   [Full Text] [Related]  

  • 8. Readers' responses to "the cost of marginal medicine is too high".
    Beard MR
    MedGenMed; 2006; 8(2):44; author reply 43. PubMed ID: 17048327
    [No Abstract]   [Full Text] [Related]  

  • 9. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
    Kavanaugh A; Cohen S; Cush JJ
    J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
    [No Abstract]   [Full Text] [Related]  

  • 10. Septic arthritis caused by Actinobacillus ureae in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha therapy.
    Kaur PP; Derk CT; Chatterji M; Dehoratius RJ
    J Rheumatol; 2004 Aug; 31(8):1663-5. PubMed ID: 15290751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
    Kievit W; Fransen J; Adang EM; Kuper HH; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; van de Laar MA; Van Riel PC
    Ann Rheum Dis; 2009 Jun; 68(6):844-9. PubMed ID: 18625616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Okamoto H
    N Engl J Med; 2006 Nov; 355(19):2047; author reply 2048. PubMed ID: 17099950
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
    Kavanaugh A
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
    [No Abstract]   [Full Text] [Related]  

  • 14. Patient access to rheumatoid arthritis treatments.
    Jönsson B
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S35-8. PubMed ID: 18157679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
    Robinson WH; Genovese MC; Moreland LW
    Arthritis Rheum; 2001 Sep; 44(9):1977-83. PubMed ID: 11592357
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
    Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
    [No Abstract]   [Full Text] [Related]  

  • 17. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
    Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
    Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TNFalpha inhibitors for the treatment of rheumatoid arthritis].
    Sany J; Kaiser MJ
    Ann Med Interne (Paris); 2002 Feb; 153(1):34-40. PubMed ID: 11994688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Dentener MA; Wouters EF
    N Engl J Med; 2006 Nov; 355(19):2047-8; author reply 2048. PubMed ID: 17099951
    [No Abstract]   [Full Text] [Related]  

  • 20. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.